PAPER Pomara N, Willoughby LM, Wesnes K, Sidtis JJ
PAPER Pomara N, Belzer K, Hernando R, De La Pena C, Sidtis JJ
Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.Am J Geriatr Psychiatry. 2008 Feb;16(2) PubMed: 18239197
MUTATIONS PSEN1 G378fs Exon 11 Insertion Coding Unknown; the insertion of one nucleotide in exon 11 is predicted to lead to a frame shift. Unknown; MRI showed hippocampal and parahippocampal atrophy. G378fs Alzheimer's Disease: PathogenicAlzheimer's Disea
JOB 2014-04-16 Employer Food and Drug Administration Contact Applications should be made to http://www.reaganudall.org/our-work/building-scientific-capacity/alzheim..., and should include: a CV; a personal statement (~500 words) describing your background, interest in t
PAPER Grant WB
PAPER Grant WB
PAPER Dauer WT, Guo M24725399
University of Utah
RESEARCH NEWS 2014-04-15 Research News A decade after the discovery that mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease, researchers are still trying to get a handle on how the giant, 51-exon, multi-catalytic protein exerts its pathogenic power. Now,
University Magna Graecia of CatanzaroCatanzaro, Italy
Bingwei Lu on Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease.
COMMENT The most important finding of the paper, in my view, is the biochemical and genetic demonstration that aberrant regulation of protein synthesis contributes to LRRK2-G2019S pathogenesis. This resonates with earlier studies in Drosophila Parkinson's di
Gaia Skibinski on Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson's Disease.
COMMENT The paper highlights the ribosomal protein S15 as a novel pathogenic LRRK2 substrate. Their hypothesis is supported by both in vivo and in vitro models of LRRK2 pathogenesis. The hypothesis that G2019S LRRK2 toxicity leads to bulk increase in protein synt
No filters selected